Sign Up Today and Learn More About Prelude Stock
Invest in or calculate the value of your shares in Prelude or other pre-IPO companies through EquityZen's platform.
Prelude Stock (PREL)
Prelude delivers actionable tools to manage early stage breast cancer with the DCIS test that enables personalized treatment.
About Prelude Stock
Founded
2009
Headquarters
Laguna Hills, CA, US
Industries
Content and Publishing, Messaging and Telecommunications, Sports
PreludeDx was founded with the goal of providing better decision-making tools to breast cancer patients and physicians. Founded in 2009 with technology licensed from the University of California San Francisco, PreludeDx has focused on developing breast cancer tools that will impact a patient’s treatment decision. Their mission is to provide tools that improve patient outcomes in breast cancer and reduce the overall cost burden to the healthcare system.
Prelude Press Mentions
Stay in the know about the latest news on Prelude
PreludeDx Receives FDA Breakthrough Device Designation for DCISionRT® Test for DCIS Breast Cancer Patients
biospace • Jan 16, 2025
Prelude raises $8M for fraud-resistant SMS verification API development
tech • Nov 13, 2024
PreludeDx Welcomes Dr. Pat Whitworth as Chief Medical Officer to Drive Expansion of Precision Diagnostics
prnewswire • May 02, 2024
PreludeDx™ Presents New Data Demonstrating Utility of DCISionRT® to De-escalate Radiation Therapy for Women with DCIS
prnewswire • Apr 14, 2024
PreludeDx Appoints Chris Emery, VP of Strategic Marketing and Business Development
prnewswire • Feb 08, 2024
Prelude Management
Leadership team at Prelude
Board of Director
Alejandro Sanchez
Chief Commercial Officer
Edwin Hendrick
Join now and verify your accreditation status to gain access to:
- Prelude Current Valuation
- Prelude Stock Price
- Prelude Management
- Available deals in Prelude and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Prelude Cap Table and Funding History by Share Class and Liquidity Preferences
- Prelude Revenue and Financials
- Prelude Highlights
- Prelude Business Model
- Prelude Risk Factors
- Prelude Research Report from SACRA Research
Trading Prelude Stock
How to invest in Prelude stock?
Accredited investors can buy pre-IPO stock in companies like Prelude through EquityZen funds. These investments are made available by existing Prelude shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Prelude stock?
Shareholders can sell their Prelude stock through EquityZen's private company marketplace. EquityZen's network includes over 360K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 46K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
